Terguride in stable Parkinson's disease.
Terguride (TER) (2 mg/day) was compared with a placebo in 41 stable Parkinson's disease (PD) patients, so as to test its efficacy as an add-on treatment to spare levodopa (LD). After the 4th week of add-on treatment, LD was reduced by about 25%. The number of "stable" patients (--those with an increase of no more than 20% of the basal Columbia University Rating Scale (CURS) score--remaining after LD reduction was used to compare the two add-on treatments. Most patients, remained "stable" in spite of LD reduction, and no significant differences between the therapies were discovered; the CURS score decreased over time only in the TER group. Hence, TER was shown to be a drug that has DA-ergic properties but with minimal antiparkinsonian efficacy.
Martignoni
E
E
Department of Neurology, Parkinson's Disease Centre, IRCCS C. Mondino, University of Pavia, Italy.
Pacchetti
C
C
Aufdembrinke
B
B
Godi
L
L
Albani
G
G
Mancini
F
F
Nappi
G
G
D000368:Aged; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007980:Levodopa / Q000378:metabolism / Q000627:therapeutic use; D008090:Lisuride / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos
D018491:Dopamine Agonists; D010919:Placebos; C006208:dironyl; D007980:Levodopa; D008090:Lisuride